Words from our CEO

Imagine waking up every morning knowing you’re part of a company with the vision of delivering world-leading cancer diagnostics for everyone. That is my reality, and it makes me fly out of bed! After more than five years of investment in technology development and domain knowledge, it became clear to us how we could make a real difference for patients and medical professionals in the shortest possible time: by building our own ultramodern digital pathology lab from scratch. This will enable us to advance faster and create greater value for patients, clinicians, and laboratory employees, including pathologists.
Specialization is a key for us because it enables brilliance. We focus on selected cancer types, starting with prostate cancer. We will later expand with additional cancer types but have no intention to cover all. Most importantly, we have no other ambition than to become world-leading within the services we offer.
Inclusion is a second key. Our services shall be available for the large mass of clinicians and patients, public and private healthcare providers.
“We bring almost 40 years of experience within advanced image analysis and AI, paired with extensive domain knowledge in pathology and medical informatics.”
Clinical pathology is currently under huge pressure, with heavy workloads and limited – even declining – resources in many places. Aging populations, increasing cancer incidence, and more frequent exams and screening programs increase the workload. Solving the problem by adding more manpower to the healthcare providers is simply not possible, as there is an acute lack of medical professionals within pathology.
There is a lot of buzz about going digital, using AI etc. to solve these current and future challenges. While I fully agree, reality shows that the transformation from analogue to digital workflows in existing clinical pathology laboratories around the world is highly complex, from a technical, legacy, and commercial perspective. Many respectable companies offer innovative, high-performing products within the field; however, no chain is stronger than its weakest link, and here, there are several. Tissue preparation processes, integration between technical innovations, human and machine integration – these are all essential to an efficient workflow. Until that integration is seamless and complete, digitalization adds limited value to clinical routine setting, and may even have negative effects in some cases.
These insights, combined with our long-term investors, are the foundation for Inify Laboratories. We bring almost 40 years of experience within advanced image analysis and AI, paired with extensive domain knowledge in pathology and medical informatics.
The backbone of our concept is to build a scalable setup where processes, machines and humans are seamlessly integrated in a standardized workflow, ensuring the utmost efficiency and quality. Only then can we deliver real enhanced patient value – and we will not compromise on that target.
“Reality shows that the transformation from analogue to digital workflows in existing clinical pathology laboratories around the world is highly complex.”
Standardized data allows for seamless, continuous development of powerful machine learning technology and process optimization within the laboratory. This in turn will provide both employed and consultant pathologists with valuable tools and prerequisites, maximizing diagnosis efficiency and quality. Inify Laboratories’ concept is scalable in volume, adaptable for additional diagnosis and expandable across geographies.
If I were to pick a single success factor, it would certainly be our cross-functional team with clinical and technical expertise, arranged in the same organization with a common goal – to improve patient care and healthcare service. 2022 is our build-up year, and I can’t wait to open our first laboratory in Stockholm, offering our services to customers within two hours’ flight range as early as possible in 2023.
Fredrik Palm
Chief Executive Officer